EGFR-TKIs (tyrosine kinase inhibitor) can effectively improve the survival rate of NSCLC patients with EGFR sensitive mutations. However, concomitant alterations along mutations often affect effect EGFR-TKIs. The genome characteristic co-mutation is great significance for guiding clinical treatment. In this study, we first reported genetic characteristics EGFR/RB1/TP53 co-variation in Chinese n...
